Skip to main content

An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

BeiGene USA, Inc.

Start Date

September 18, 2023

End Date

September 14, 2028
 

Administered By

Duke Cancer Institute

Awarded By

BeiGene USA, Inc.

Start Date

September 18, 2023

End Date

September 14, 2028